FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.

This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

As of last week, Chris Klomp is in charge of the Center for Medicare. Unlike predecessors, he’s not a policy wonk. Klomp was ...

Some telehealth companies that offered compounded GLP-1s have disappeared altogether. Others are pursuing strategies that ...

Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

There is common ground. Most adults favor: Preventing chronic diseases (Republicans 86%, Democrats 91%) Protecting against ...

Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies ...

Stealth BioTherapeutics had expected the FDA to respond on Tuesday to its marketing application for elamipretide to treat ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

If the law is struck down or any ambiguity left surrounding its validity, coverage of and access to preventive care like PrEP ...

With a May 24 deadline looming, Kennedy's MAHA commission has held just one full meeting on its goal of reducing childhood ...

Many Medicare quality measures are only loosely related to actual patient outcomes. It’s time to deregulate the system, ...